Journal Mobile Options
Table of Contents
Vol. 2, No. 6, 2005
Issue release date: May 2006
Section title: Original Paper
Neurodegenerative Dis 2005;2:299–304
(DOI:10.1159/000092316)

Plasma Homocysteine and Risk of Coexisting Silent Brain Infarction in Alzheimer’s Disease

Matsui T. · Nemoto M. · Maruyama M. · Yuzuriha T. · Yao H. · Tanji H. · Ootsuki M. · Tomita N. · Matsushita S. · Higuchi S. · Yoshida Y. · Seki T. · Iwasaki K. · Furukawa K. · Arai H.
aDepartment of Geriatric and Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, bCenter for Emotional and Behavioral Disorders, National Hospital Organization, Hizen Psychiatric Center, Saga, cDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, dNational Hospital Organization, Kurihama Alcoholism Center, Yokosuka, eOnagawa Municipal Hospital, Onagawa, and fCenter for Asian Traditional Medicine Research, Department of Geriatric and Complementary Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 10/24/2005
Accepted: 1/23/2006
Published online: 5/5/2006
Issue release date: May 2006

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 2

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD

Abstract

Background: Cerebrovascular disease is common in Alzheimer’s disease (AD). Elevated plasma homocysteine (pHcy) levels are reported to be associated with an increased risk of poor cognition and dementia. Objective: To determine whether high pHcy levels are associated with an increased risk of coexisting silent brain infarctions (SBIs) in AD. Methods: Study population comprising 143 outpatients with clinical diagnosis of probable AD (73.3 ± 7.0 years) were classified into 2 groups according to the presence or absence of SBIs on magnetic resonance imaging. Results: SBIs were noted in 32.9% (47/143) of the AD patients. The pHcy levels in the AD with SBIs (14.0 ± 4.5 µmol/l) were significant ly elevated compared with the AD without SBIs (11.7 ± 4.7 µmol/l, p = 0.007). After adjusting for age and gender, high pHcy (>12.4 µmol/l), but not hypertension, was associated with an increased risk of developing SBIs in AD (OR = 4.61, 95% CI = 1.74–12.2, p = 0.002). However, age at onset, cognitive function, cerebrospinal tau or amyloid β-peptide1–42 levels were not significantly correlated with pHcy levels in AD. Conclusion: SBIs commonly coexist with AD, and may be a unique vascular condition in which homocysteine plays an important role. Homocysteine-lowering therapy rather than antihypertensive medication might be an appropriate strategy to prevent stroke associated with AD.


  

Author Contacts

Hiroyuki Arai, MD, PhD
Center for Asian Traditional Medicine Research
Department of Geriatric and Complementary Medicine
Tohoku University Graduate School of Medicine, Sendai 980-8574 (Japan)
Tel. +81 22 717 7182, Fax +81 22 717 7186, E-Mail harai@geriat.med.tohoku.ac.jp

  

Article Information

Received: October 24, 2005
Accepted after revision: January 23, 2006
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 2, Number of References : 25

  

Publication Details

Neurodegenerative Diseases

Vol. 2, No. 6, Year 2005 (Cover Date: May 2006)

Journal Editor: Nitsch, R.M. (Zürich)
ISSN: 1660–2854 (print), 1660–2862 (Online)

For additional information: http://www.karger.com/NDD


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 10/24/2005
Accepted: 1/23/2006
Published online: 5/5/2006
Issue release date: May 2006

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 2

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.